ObvioHealth says its new decentralized clinical trial application for mobile devices will help sponsors and CROs generate safety and efficacy data more effectively.
The technology – called ObvioGo – is billed as technology for capturing more accurate multi-source data, providing a unified platform that empowers clinical science teams to generate stronger therapeutic evidence.
The system supports capabilities like study design, data capture, assessment and clinical trial and data management.
Ivan Jarry, CEO of ObvioHealth said the app has been developed using insights gained from more than 50 fully virtual and hybrid trials in 28 countries, predicting it “will propel the industry forward.”
This was echoed by chief technology officer Craig Gravina, who cited the systems use of combined cloud-native and AI-enriched technologies as its key feature.
“Our machine learning technologies remove repetitive tasks while providing deeper insights. By automating low-value processes, we are enabling humans—both patients and clinicians—to focus on the added value efforts that deliver stronger outcomes.”
Technology
Obviohealth was launched in 2017 when SPRIM and Tikehau Capital partnered to establish a venture capital fund called TKS1. At the time the firm said it planned to develop a remote trial tech ecosystem through partnerships and investment.
The app launch is the second expansion of ObvioHealth’s mobile trials offering in recent months. In July the firm expanded its deal with Dedalus Group, a software developer focused on clinical trials.
Under the expanded agreement ObvioHealth can use Dedalus's data mining and analytics tools for their own research as well as that of its partners and sponsors.
At the time ObvioHealth said the technology would enable access to analytics of its own multi-source healthcare data to inform better clinical trial design and recruitment as well as longitudinal disease and treatment trends.
Image/AdobeStock